JANX vs PYXS
JANX: Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of cancer and autoimmune treatments. PYXS: Pyxis Oncology is a clinical-stage biopharma developing innovative antibody-drug conjugates (ADCs) that target the tumor microenvironment to improve efficacy in difficult-to-treat solid tumors.
Side-by-side fundamentals
| Metric | JANX | PYXS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.62 | $2.53 | |
| Market cap as of 2026-07-23 | $953M | $160M | |
| PEG as of 2026-07-23 | -0.25 | n/a | |
| Net margin as of 2026-07-23 | -354.4% | -574.5% | JANX higher |
| Gross margin as of 2026-07-23 | n/a | +82.8% | |
| Operating margin as of 2026-07-23 | -505.8% | -609.2% | JANX higher |
| ROE as of 2026-07-23 | -11.8% | -70.8% | JANX higher |
| ROA as of 2026-07-23 | -11.2% | -49.3% | JANX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | JANX lower |
| Revenue growth (YoY) as of 2026-07-23 | +47.1% | -14.2% | JANX higher |
| Beta as of 2026-07-23 | 2.53 | 1.32 | |
| 1-year return as of 2026-07-22 close | -37.7% | +97.3% | PYXS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.